<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378531</url>
  </required_header>
  <id_info>
    <org_study_id>CAEB1102-102A</org_study_id>
    <nct_id>NCT03378531</nct_id>
  </id_info>
  <brief_title>A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency</brief_title>
  <acronym>AEB1102</acronym>
  <official_title>An Open-label, Multicentre Extension Study to Evaluate the Long-Term Safety, Tolerability and Effects of Intravenous AEB1102 in Patients With Arginase I Deficiency Who Previously Received Treatment in Study CAEB1102-101A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeglea Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeglea Biotherapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the long-term safety, tolerability,
      immunogenicity, pharmacokinetics and pharmacodynamics of intravenous AEB1102 in patients who
      complete Study CAEB1102-101A.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-related adverse events</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax Cmin</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Arginase I Deficiency</condition>
  <condition>Hyperargininemia</condition>
  <arm_group>
    <arm_group_label>AEB1102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient may receive AEB1102 administered IV for up to approximately 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEB1102</intervention_name>
    <description>modified human arginase I</description>
    <arm_group_label>AEB1102</arm_group_label>
    <other_name>Co-ArgI-PEG</other_name>
    <other_name>Pegzilarginase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Complete treatment in Study CAEB1102-101A without experiencing any clinically
             significant adverse event or other unmanageable drug toxicity that would preclude
             continued dosing

          2. Confirmation by the Investigator and the Sponsor determine that it is acceptable for
             the patient to continue dosing with AEB1102

          3. If female and of child-bearing potential, has a negative serum pregnancy test within 7
             days before enrollment

          4. If sexually active (male or female), must be surgically sterile, post-menopausal
             (female), or must agree to use a physician-approved method of birth control during the
             study and for a minimum of 30 days after the last study drug administration

          5. Patient or legal guardian is able and willing to provide written informed consent and
             where required assent, and to comply with all requirements of study participation
             (including all study procedures and continuation of prescribed diet without
             modification), prior to any screening procedures

        Exclusion Criteria:

        1. Clinically significant concurrent disease, serious intercurrent illness, or other
        extenuating circumstances
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Joffrion</last_name>
    <role>Study Director</role>
    <affiliation>Aeglea Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aeglea Clinical Department</last_name>
    <phone>1.855.509.9921</phone>
    <email>raredisease@aegleabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Zori, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Zori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Diaz, MD</last_name>
    </contact>
    <investigator>
      <last_name>George Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperargininemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

